| An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase Alfa (human recombinant tissue non-specific alkaline phosphatase fusion protein) in Infants and Children ≤ 5 Years of Age with Hypophosphatasia (HPP). |
Completed |
Asfotase Alfa |
2 |
ENB-010-10 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Efficacy and Safety of Irbesartan/Amlodipine Fixed Combination Therapy Compared With Irbesartan Monotherapy in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy |
Completed |
Irbesartan Amlodipine |
3 |
IRBAM_R_04219 |
King Abdulaziz Medical City NG (Jeddah) |
| Phase IIb Primary Vaccination Study to Evaluate Non-Inferiority & Persistence of the Immune Response of GSK Biologicals' MenACWY Conjugate Vaccine (Intramuscularly) vs Mencevax ACWY (Subcutaneously) to Healthy Subjects (11-55 Years of Age) |
Completed |
Meningococcal ACWY Conjugate Vaccine |
3b |
107402 |
King Abdulaziz Medical City NG (Riyadh) |
| Tocilizumab Efficacy and Safety in RA Patients After Inadequate Response to DMARDs or Anti-TNF |
Completed |
Tocilizumab |
3 |
ML22726 |
King Fahad Specialist Hospital (Dammam), King Fahad Medical City (Riyadh), King Abdulaziz University Hospital (Jeddah), Hira Hospital (Makkah) |
| An Open Label, Randomised Phase III Trial of BIBW 2992 and Vinorelbine Versus Trastuzumab and Vinorelbine in Patients With Metastatic HER2-overexpressing Breast Cancer Failing One Prior Trastuzumab Treatment |
Completed |
BIBW 2992 / Vinorelbine / Trastuzumab |
3 |
1200.75 |
King Fahad Medical City (Riyadh), International Medical Center (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah) |
| V212-001 A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients With Solid Tumor or Hematologic Malignancy |
Completed |
V212 |
3 |
V212-011 |
King Fahad Specialist Hospital (Dammam) |
| A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) |
Completed |
BMN 110 |
3 |
MOR-005 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Randomized, Open-label Phase III Intergroup Study: Effect of Adding Bevacizumab to Cross Over Fluoropyrimidine Based Chemotherapy (CTx) in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line Standard CTx/Bevacizumab Combination |
Completed |
Bevacizumab |
3 |
ML18147 |
King Fahad Specialist Hospital (Dammam), King Abdulaziz Hospital and Oncology Center (Jeddah), King Abdulaziz University Hospital (Jeddah), King Faisal Specialist Hospital and Research Center (Jeddah), King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multinational Clinical Study to Evaluate the Efficacy and Safety of 2.0 mg/kg/Week and 2.0 mg/kg/Every Other Week BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) |
Completed |
BMN 110 |
3 |
MOR-004 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Multi-Center Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have An Inadequate Response to Current Non-Biologic DMARD or Anti-TNF Therapy |
Completed |
Tocilzumab |
3b |
MA21573 |
King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Jeddah), King Abdulaziz University Hospital (Jeddah) |
